ESCMID Global Congress 2026

The Lancet Microbe · Published 2026-06-01 · DOI 10.1016/j.lanmic.2026.101476

Free full text

Authors (1)

Priya Venkatesan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Venkatesan, P. (2026). ESCMID Global Congress 2026. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2026.101476

Related articles

• VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial · The Lancet Microbe · 2026 · Same journal
• Context-dependent and ecological drivers of neonatal invasive Escherichia coli population dynamics—Authors’ reply · The Lancet Microbe · 2026 · Same journal
• Interchangeability of blood culture bottles and automats for blood culture systems: an in-vitro performance evaluation · The Lancet Microbe · 2026 · Same journal
• The hantavirus question we are not asking · The Lancet Microbe · 2026 · Same journal
• Evaluation of the effectiveness of artemether–lumefantrine and artesunate–pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial · The Lancet Microbe · 2026 · Same journal
• Genotype-based antimicrobial resistance tests need a new regulatory framework · The Lancet Microbe · 2026 · Same journal
• Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study · The Lancet Microbe · 2026 · Same journal
• Strengthening pre-spillover surveillance: the missing link in Ebola preparedness · The Lancet Microbe · 2026 · Same journal
• Andes virus induces a chemokine-dominant endothelial and stromal activation pattern that promotes immune-cell recruitment · The Lancet Microbe · 2026 · Same journal
• Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial · The Lancet Microbe · 2026 · Same journal